Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Total Debt (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Total Debt for 6 consecutive years, with $54.0 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 46.16% to $54.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.0 million through Dec 2025, down 46.16% year-over-year, with the annual reading at $54.0 million for FY2025, 46.16% down from the prior year.
  • Total Debt for Q4 2025 was $54.0 million at Lexicon Pharmaceuticals, down from $56.5 million in the prior quarter.
  • The five-year high for Total Debt was $100.7 million in Q1 2025, with the low at $48.8 million in Q1 2023.
  • Average Total Debt over 3 years is $84.4 million, with a median of $99.4 million recorded in 2023.
  • The sharpest move saw Total Debt soared 104.47% in 2024, then plummeted 46.16% in 2025.
  • Over 3 years, Total Debt stood at $99.5 million in 2023, then grew by 0.79% to $100.3 million in 2024, then tumbled by 46.16% to $54.0 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $54.0 million, $56.5 million, and $56.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.